國立虎尾科技大學 |

Artificial Intelligence in Drug Design

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Artificial Intelligence in Drug Design/ edited by Alexander Heifetz.
other author:	Heifetz, Alexander.
Description:	XI, 529 p. 103 illus., 89 illus. in color.online resource. :
Contained By:	Springer Nature eBook
Subject:	Pharmacology. -
Online resource:	https://doi.org/10.1007/978-1-0716-1787-8
ISBN:	9781071617878

Artificial Intelligence in Drug Design
Artificial Intelligence in Drug Design[electronic resource] /edited by Alexander Heifetz. - 1st ed. 2022. - XI, 529 p. 103 illus., 89 illus. in color.online resource. - Methods in Molecular Biology,23901940-6029 ;. - Methods in Molecular Biology,2540.

Applications of Artificial Intelligence in Drug Design: Opportunities and Challenges -- Machine Learning Applied to the Modeling of Pharmacological and ADMET Endpoints -- Fighting COVID-19 with Artificial Intelligence -- Application of Artificial Intelligence and Machine Learning in Drug Discovery -- Deep Learning and Computational Chemistry -- Has Drug Design Augmented by Artificial Intelligence Become a Reality? -- Network Driven Drug Discovery -- Predicting Residence Time of GPCR Ligands with Machine Learning -- De Novo Molecular Design with Chemical Language Models -- Deep Neural Networks for QSAR -- Deep Learning in Structure-Based Drug Design -- Deep Learning Applied to Ligand-Based De Novo Drug Design -- Ultra-High Throughput Protein-Ligand Docking with Deep Learning -- Artificial Intelligence and Quantum Computing as the Next Pharma Disruptors -- Artificial Intelligence in Compound Design -- Artificial Intelligence, Machine Learning, and Deep Learning in Real Life Drug Design Cases -- Artificial Intelligence-Enabled De Novo Design of Novel Compounds that are Synthesizable -- Machine Learning from Omics Data -- Deep Learning in Therapeutic Antibody Development -- Machine Learning for In Silico ADMET Prediction -- Opportunities and Considerations in the Application of Artificial Intelligence to Pharmacokinetic Prediction -- Artificial Intelligence in Drug Safety and Metabolism -- Molecule Ideation Using Matched Molecular Pairs.

This volume looks at applications of artificial intelligence (AI), machine learning (ML), and deep learning (DL) in drug design. The chapters in this book describe how AI/ML/DL approaches can be applied to accelerate and revolutionize traditional drug design approaches such as: structure- and ligand-based, augmented and multi-objective de novo drug design, SAR and big data analysis, prediction of binding/activity, ADMET, pharmacokinetics and drug-target residence time, precision medicine and selection of favorable chemical synthetic routes. How broadly are these approaches applied and where do they maximally impact productivity today and potentially in the near future. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary software and tools, step-by-step, readily reproducible modeling protocols, and tips on troubleshooting and avoiding known pitfalls. Cutting-edge and unique, Artificial Intelligence in Drug Design is a valuable resource for structural and molecular biologists, computational and medicinal chemists, pharmacologists and drug designers.

ISBN: 9781071617878

Standard No.: 10.1007/978-1-0716-1787-8doiSubjects--Topical Terms:

583819
Pharmacology.

LC Class. No.: RM300-666

Dewey Class. No.: 615

Artificial Intelligence in Drug Design
LDR:03918nam a22003855i 4500 001 1090510
003 DE-He213
005 20220118060948.0
007 cr nn 008mamaa
008 221228s2022 xxu| s |||| 0|eng d
020 $a 9781071617878 $9 978-1-0716-1787-8
024 7 $a 10.1007/978-1-0716-1787-8 $2 doi
035 $a 978-1-0716-1787-8
050 4 $a RM300-666
072 7 $a MMG $2 bicssc
072 7 $a MED071000 $2 bisacsh
072 7 $a MKG $2 thema
082 0 4 $a 615 $2 23
245 1 0 $a Artificial Intelligence in Drug Design $h [electronic resource] / $c edited by Alexander Heifetz.
250 $a 1st ed. 2022.
264 1 $a New York, NY : $b Springer US : $b Imprint: Humana, $c 2022.
300 $a XI, 529 p. 103 illus., 89 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Methods in Molecular Biology, $x 1940-6029 ; $v 2390
505 0 $a Applications of Artificial Intelligence in Drug Design: Opportunities and Challenges -- Machine Learning Applied to the Modeling of Pharmacological and ADMET Endpoints -- Fighting COVID-19 with Artificial Intelligence -- Application of Artificial Intelligence and Machine Learning in Drug Discovery -- Deep Learning and Computational Chemistry -- Has Drug Design Augmented by Artificial Intelligence Become a Reality? -- Network Driven Drug Discovery -- Predicting Residence Time of GPCR Ligands with Machine Learning -- De Novo Molecular Design with Chemical Language Models -- Deep Neural Networks for QSAR -- Deep Learning in Structure-Based Drug Design -- Deep Learning Applied to Ligand-Based De Novo Drug Design -- Ultra-High Throughput Protein-Ligand Docking with Deep Learning -- Artificial Intelligence and Quantum Computing as the Next Pharma Disruptors -- Artificial Intelligence in Compound Design -- Artificial Intelligence, Machine Learning, and Deep Learning in Real Life Drug Design Cases -- Artificial Intelligence-Enabled De Novo Design of Novel Compounds that are Synthesizable -- Machine Learning from Omics Data -- Deep Learning in Therapeutic Antibody Development -- Machine Learning for In Silico ADMET Prediction -- Opportunities and Considerations in the Application of Artificial Intelligence to Pharmacokinetic Prediction -- Artificial Intelligence in Drug Safety and Metabolism -- Molecule Ideation Using Matched Molecular Pairs.
520 $a This volume looks at applications of artificial intelligence (AI), machine learning (ML), and deep learning (DL) in drug design. The chapters in this book describe how AI/ML/DL approaches can be applied to accelerate and revolutionize traditional drug design approaches such as: structure- and ligand-based, augmented and multi-objective de novo drug design, SAR and big data analysis, prediction of binding/activity, ADMET, pharmacokinetics and drug-target residence time, precision medicine and selection of favorable chemical synthetic routes. How broadly are these approaches applied and where do they maximally impact productivity today and potentially in the near future. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary software and tools, step-by-step, readily reproducible modeling protocols, and tips on troubleshooting and avoiding known pitfalls. Cutting-edge and unique, Artificial Intelligence in Drug Design is a valuable resource for structural and molecular biologists, computational and medicinal chemists, pharmacologists and drug designers.
650 0 $a Pharmacology. $3 583819
650 0 $a Artificial intelligence. $3 559380
650 0 $a Machine learning. $3 561253
650 2 4 $a Artificial Intelligence. $3 646849
650 2 4 $a Machine Learning. $3 1137723
700 1 $a Heifetz, Alexander. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1397939
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9781071617861
776 0 8 $i Printed edition: $z 9781071617885
776 0 8 $i Printed edition: $z 9781071617892
830 0 $a Methods in Molecular Biology, $x 1940-6029 ; $v 2540 $3 1387604
856 4 0 $u https://doi.org/10.1007/978-1-0716-1787-8
912 $a ZDB-2-PRO
950 $a Springer Protocols (Springer-12345)